> Methods: For the open-label stage of clinical trial NCT02548559, autoregressive linear modeling assessed efficacy and tolerability of four-weeks of 1 mL t.i.d

> Methods: For the open-label stage of clinical trial NCT02548559, autoregressive linear modeling assessed efficacy and tolerability of four-weeks of 1 mL t.i.d. treatment with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL Δ-9-tetrahydrocannabinol) in 14 outpatients with moderate-to-severe anxiety, defined as ≥16 on the Beck Anxiety Inventory (BAI) or ≥11 on the Overall Anxiety Severity and Impairment Scale (OASIS). Sorry, but mental health studies without a placebo control group are useless. It's well known that placebo groups have a very strong response in these studies. Unless you have a control group, you have no idea if the effects are due to the active drug or due to involvement in the study. Also, it doesn't make sense for them to use a THC-inclusive blend and then attribute the effects entirely to CBD. The amount of THC consumed by patients per day was about 0.7mg sublingually. That's not enough to get people "high" but it is enough to be relevant for the drug's effects. This is not a good study. I'm surprised to see this attached to Harvard.